Young adults using both e-cigarettes and combustible cigarettes at significantly higher risk of stroke

A new study in the American Journal of Preventive Medicine shows that switching from combustible to e-cigarettes does not reduce stroke risk

Ann Arbor, January 7, 2020 – People are looking at e-cigarettes as a “healthy” alternative to cigarettes and we currently have an epidemic of e-cigarettes use. However, according to a new study in the American Journal of Preventive Medicine, published by Elsevier, young adults who smoke cigarettes plus use e-cigarettes are nearly two times more likely to have a stroke compared to current cigarette-only smokers and nearly three times more likely than non-smokers.

“It’s long been known that smoking cigarettes is among the most significant risk factors for stroke. Our study shows that young smokers who also use e-cigarettes put themselves at an even greater risk,” explained lead investigator Tarang Parekh, MBBS, MSc, Department of Health Administration and Policy, George Mason University, Fairfax, VA, USA. “This is an important message for young smokers who perceive e-cigarettes as less harmful and consider them a safer alternative. We have begun understanding the health impact of e-cigarettes and concomitant cigarette smoking, and it’s not good.”

E-cigarettes may not be a safe way to stop smoking, the claim made by their purveyors. Researchers are only beginning to understand the health consequences of e-cigarettes, but the case against them is mounting with recent instances of vaping-related lung injury, as well as studies showing their hazards as a gateway (e-cigarettes users are more likely to start smoking within a shorter period of time than non-users), long-term source of high nicotine concentration, and their role in an inflammatory signaling network that underlies cardiovascular disease.

“Our findings demonstrate an additive harmful effect of e-cigarettes on smokers’ blood vessels, hearts and brains,” explained Mr. Parekh. This study calculated the adjusted odds ratios (AORs) for cerebrovascular events among current smokers (compared to non-smokers) at 1.59, former smokers who have switched to e-cigarettes at 2.54, and those who use both at 2.91. Factors weighed in this ratio included frequency of use; demographic factors; hypertension, diabetes, and cholesterol levels; body mass index; physical activity; and alcohol use.
E-cigarette use by never-smokers is not associated with an increased stroke risk, which is potentially due to relatively young age of sole e-cigarette users with better socioeconomic status, higher insurance enrollment, and normal cardiovascular health that could overall undermine the stroke risk. Therefore, it remains important to analyze long-term effects of e-cigarette smoking on cerebrovascular metabolism before completely dismissing a higher stroke risk. This study also did not find any clear benefit from using e-cigarettes if users are switching from combustible cigarette smoking.

Investigators used data from the 2016–2017 Behavior Risk Factor Surveillance System (BRFSS), a national annual, cross-sectional health survey conducted jointly by the Centers for Disease Control and Prevention and all US states and territories to investigate the prevalence and effect of e-cigarette and combustible cigarette use among young adults. They analyzed responses on cigarette and e-cigarette use from 161,529 participants aged 18–44 years. A slight majority of the sample population was female (53.1 percent), white (50.6 percent), and unmarried (50.3 percent). Nearly half had annual incomes over $50,000 and just under a quarter identified as Hispanic. Compared with non-smokers, e-cigarette users (solo and concomitantly with smoking) reported higher rates of college dropout / terminal high-school, unmarried status, obesity, and binge drinking.

Although e-cigarettes are labeled by some as a “safer option” to active smoking cessation, nicotine dependence and toxicity remain a great concern in low-risk young adults who smoke e-cigarettes for flavors and fun. “Consider this study as a wake-up call for young vapers, clinicians, and healthcare policymakers. There is an urgency to regulate such products to avoid economic and population health consequences and a critical need to conduct further research on the benefits and risks of smoking-cessation alternatives,” warned Mr. Parekh.

---

Notes for editors

Full text of this article is available to credentialed journalists upon request; contact Jillian B. Morgan at +1 734 936 1590 or ajpmedia@elsevier.com. Journalists wishing to interview the authors should contact Tarang Parekh at drtarangparekh@gmail.com.

About the American Journal of Preventive Medicine
The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials. www.ajpmonline.org
About Elsevier

Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com